Translational Center for In Vivo Mitochondrial Medicine
Description: NARRATIVE This work is relevant to human health because mitochondrial dysfunction is involved in most degenerative diseases, including diabetes, Parkinson's disease, Huntington's disease, and normal aging. However, there is a gap in our understanding of the role of mitochondrial dysfunction in these diseases due to a gap in our tools study mitochondrial function in vivo. We propose to create a new Translational Center for In Vivo Mitochondrial Medicine to further develop and expand our unique tools for in vivo study of mitochondrial function and cell energetics. This new initiative will facilitate new insights into the conditions that determine whether energetic stress leads to cell adaptation, as in healthy tissue, or cell loss and degeneration, as in diseases states. The goal of this new center will be to make our in vivo approach accessible to the broader research community to accelerate critical breakthroughs and translate these breakthroughs into clinical applications. The requested funds will be used to hire and train at least five new long-term positions and expand the infrastructure to increase the throughput of our experiments and analyses.
Funder: National Institute on Aging
Funding type: research
Funder scheme: RC2
Start date: 2009-09-30
End date: 2012-08-31
Investigator: KEVIN E CONLEY
Institution: UNIVERSITY OF WASHINGTON
Subfield: Molecular Biology
Domain: Life Sciences
Funded outputs count: 23
Funder award ID: RC2AG036606
OpenAlex ID: G763945140